Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASH 2019 | Predictive biomarkers of response to VenBd in R/R MM

Michael O’Dwyer • 7 Dec 2019
ASH 2019
Multiple Myeloma Bortezomib Dexamethasone Venetoclax
BELLINI

Michael O’Dwyer, MD, PhD, National University of Ireland, Galway, Ireland, discusses the biomarker analysis from the phase III BELLINI study (NCT02755597) of venetoclax in combination with bortezomib and dexamethasone (VenBd) in patients with relapsed/refractory (R/R) multiple myeloma (MM). This revealed that VenBd shows significant efficacy in patients harboring either t(11;14) or with tumor cells expressing high levels of BCL2. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Michael O’Dwyer

ST3GAL1 as a novel biomarker of lack of sustained MRD negativity in multiple myeloma 8:47
ST3GAL1 as a novel biomarker of lack of sustained MRD negativity in multiple myeloma
Michael O’Dwyer • 12 Dec 2024
Genomic and transcriptomic analysis of R/R myeloma in the Phase III BELLINI study 3:31
Genomic and transcriptomic analysis of R/R myeloma in the Phase III BELLINI study
Michael O’Dwyer • 30 Nov 2020
Current myeloma cellular therapy landscape and horizon scan 5:14
Current myeloma cellular therapy landscape and horizon scan
Michael O’Dwyer • 30 Nov 2020
Cellular therapy: NK-cells as a model 2:01
Cellular therapy: NK-cells as a model
Michael O’Dwyer • 21 May 2020

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals